Patents-Review.com
ClassID:

110413 ⎘

C12N2740/16111 - CPC Classification

Classification description:

Reverse transcribing RNA viruses; Details; Retroviridae; Human Immunodeficiency Virus, HIV concerning HIV env

Sub-classes:
Recent Application in this class:
#1
20250320281
2025-10-16

METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES

 #2
20250320280
2025-10-16

BROADLY NEUTRALIZING ANTIBODIES THAT TARGET HIV ENV V3 N-GLYCANS

 #3
20250115661
2025-04-10

BROADLY NEUTRALIZING ANTI-HIV ANTIBODIES AND EPITOPE THEREFOR

 #4
20250066457
2025-02-27

ANTIBODIES TARGETING HIV ESCAPE MUTANTS

 #5
20240424082
2024-12-26

GLYCAN-MASKED ENGINEERED OUTER DOMAINS OF HIV-1 GP120 AND THEIR USE

 #6
20240417449
2024-12-19

HIGHLY ACTIVE AGONISTIC CD4 BINDING SITE ANTI-HIV ANTIBODIES (HAADS) COMPRISING MODIFIED CDRH2 REGIONS THAT IMPROVE CONTACT WITH GP120

 #7
20240295558
2024-09-05

Metal Nanoparticles And Method Of Making Same

 #8
20240132578
2024-04-25

METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES

 #9
20230279082
2023-09-07

Broadly-Neutralizing HIV Antibodies

 #10
20230192823
2023-06-22

Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120

 #11
20230167178
2023-06-01

Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof

 #12
20230027965
2023-01-26

Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies

 #13
20220169707
2022-06-02

HIV-1 gp120 CD4 binding site antibodies targeting HIV escape mutants

 #14
20220152194
2022-05-19

Glycan-masked engineered outer domains of HIV-1 gp120 and their use

 #15
20220002391
2022-01-06

Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor

 #16
20220002390
2022-01-06

Broadly-neutralizing anti-HIV antibodies

 #17
20210317169
2021-10-14

STABILIZED HUMAN IMMUNODEFICIENCY VIRUS (HIV) ENVELOPE (ENV) TRIMER VACCINES AND METHODS OF USING SAME

 #18
20210275592
2021-09-09

Immune cells with DNMT3A gene modifications and methods related thereto

 #19
20210220468
2021-07-22

Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins

 #20
20210138060
2021-05-13

Multimodal chromatography method for the purification of HIV-1 envelope glycoprotein

 #21
20210102221
2021-04-08

Methods and compositions for a HIV based delivery system

 #22
20210101963
2021-04-08

Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope

 #23
20210095021
2021-04-01

Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof

 #24
20200390908
2020-12-17

Metal nanoparticles and methods of making same

 #25
20200165325
2020-05-28

Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120

 #26
20200140528
2020-05-07

Nucleic acids encoding broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 ENV subunits

 #27
20200129618
2020-04-30

Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies in subjects with low viral loads

 #28
20200121783
2020-04-23

Glycan-masked engineered outer domains of HIV-1 gp120 and their use

 #29
20200024330
2020-01-23

Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies

 #30
20190367587
2019-12-05

VC-CAR molecule and use thereof in removing HIV-1 infected cells

 #31
20190345233
2019-11-14

Broadly-neutralizing anti-HIV antibodies

 #32
20190339274
2019-11-07

Method for detecting HIV-1 co-receptor tropism

 #33
20190321462
2019-10-24

Recombinant adenoviruses encoding mosaic human immunodeficiency virus (HIV) Env, Gag, and Pol antigens

 #34
20190185549
2019-06-20

Broadly cross-reactive HIV-1-specific antibodies for prevention and treatment of HIV

 #35
20190119699
2019-04-25

LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA

 #36
20190085058
2019-03-21

DNA antibody constructs and method of using same

 #37
20190055290
2019-02-21

Stabilized human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using same

 #38
20190048067
2019-02-14

Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope

 #39
20180346928
2018-12-06

LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA

 #40
20180318350
2018-11-08

Immune cells with DNMT3A gene modifications and methods related thereto

 #41
20180237506
2018-08-23

Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with gp120

 #42
20180230203
2018-08-16

HIV-1 GP120 CD4 binding site antibodies targeting HIV escape mutants

 #43
20180194811
2018-07-12

Method of inducing an immune response against human immunodeficiency virus comprising administering immunogenic compositions comprising authentic trimeric HIV-1 envelope glycoproteins containing a long linker and tag

 #44
20180186839
2018-07-05

Stabilized human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using same

 #45
20180161423
2018-06-14

Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies

 #46
20180155423
2018-06-07

Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof

 #47
20180066023
2018-03-08

Method of purifying authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag

 #48
20170369558
2017-12-28

Neutralizing antibodies to HIV-1 and their use

 #49
20170247453
2017-08-31

Soluble engineered monomeric Fc

 #50
20170165355
2017-06-15

Synthetic human immunodeficiency virus (HIV) envelope antigen, vectors, and compositions thereof

 #51
20170095551
2017-04-06

Replication-competent VSV-HIV Env vaccines

 #52
20170067878
2017-03-09

Methods for determining susceptibility to coreceptor inhibitors

 #53
20170014474
2017-01-19

Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4

 #54
20160355545
2016-12-08

Method for improving protein functionality using vortexing fluid shear forces

 #55
20160354462
2016-12-08

Vaccine and therapeutic delivery system

 #56
20160339051
2016-11-24

Methods for reducing HIV-1 mother-to-child transmission by inducing V3-specific or CD4 binding site-specific antibodies

 #57
20160311891
2016-10-27

DNA antibody constructs and method of using same

 #58
20160272686
2016-09-22

Approach to produce HIV-1 GP140 envelope protein trimers

 #59
20160272685
2016-09-22

Method of purifying authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag

 #60
20160272684
2016-09-22

Authentic trimeric HIV-1 GP140 envelope glycoproteins comprising a long linker and tag

 #61
20160271243
2016-09-22

Authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag

 #62
20160243215
2016-08-25

Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same

 #63
20160017038
2016-01-21

Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof

 #64
20160009789
2016-01-14

Neutralizing antibodies to HIV-1 and their use

 #65
20150306174
2015-10-29

Stabilized trimeric HIV-1 GP41 fusion inhibitor polypeptides comprising the N-terminal heptad repeat (NHR) and foldon (FD) trimerization motif

 #66
20150191745
2015-07-09

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

 #67
20150175666
2015-06-25

PEPTIDES DERIVED FROM HIV GP41 FOR TREATING T-CELL MEDIATED PATHOLOGIES

 #68
20150098965
2015-04-09

Immunogenic compositions comprising FIV and HIV gag antigens

 #69
20150050278
2015-02-19

Soluble engineered monomeric Fc

 #70
20150011006
2015-01-08

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

 #71
20140302080
2014-10-09

Stabilized mosaic human immunodeficiency virus type 1 (HIV-1) GP140 envelope (ENV) trimers

 #72
20130149323
2013-06-13

Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties

 #73
20130143202
2013-06-06

Method for the detection of HIV-1 antibodies utilizing a peptide containing a novel gp41 epitope

 #74
20130034843
2013-02-07

Molecular determinants in the HIV-1 envelope associated with enhanced ability to enter CXCR4-expressing cells

 #75
20130011414
2013-01-10

Broadly cross-reactive HIV-1 Env-specific antibodies

 #76
20120294891
2012-11-22

MATERIALS AND METHODS FOR DETECTING, PREVENTING, AND TREATING RETROVIRAL INFECTION

 #77
20120288502
2012-11-15

Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120

 #78
20120282264
2012-11-08

Neutralizing antibodies to HIV-1 and their use

 #79
20120244166
2012-09-27

NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE

 #80
20120237523
2012-09-20

Neutralizing antibodies to HIV-1 and their use

 #81
20120214151
2012-08-23

Detection of HIV-related proteins in urine

 #82
20120208175
2012-08-16

Detection of HIV-related proteins in urine

 #83
20120183597
2012-07-19

Method of inducing neutralizing antibodies to human immunodeficiency virus

 #84
20120122963
2012-05-17

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

 #85
20120122204
2012-05-17

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

 #86
20120107910
2012-05-03

Recombinant HIV-1 envelope proteins comprising stabilizing two-cysteine mini-domains in gp41

 #87
20120046221
2012-02-23

Albumin fusion proteins

 #88
20110201035
2011-08-18

Methods for the detection of HIV-1-specific antibodies employing GP41 polypeptides

 #89
20110151436
2011-06-23

COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION

 #90
20110086028
2011-04-14

Method of inhibiting HIV-1 binding to genital epithelia using V3 loop-specific peptides and GP340-specific antibodies

 #91
20110009312
2011-01-13

Albumin fusion proteins

 #92
20100204120
2010-08-12

Stabilized trimeric HIV-1 gp41 fusion polypeptides comprising the N-terminal heptad repeat (NHR) and foldon (FD) trimerization motif

 #93
20100143291
2010-06-10

Inactivated pepsin fragments for modulating immune system activity against human malignant tumor cells

 #94
20100086956
2010-04-08

Detection of HIV-related proteins in urine

 #95
20100074904
2010-03-25

Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4

 #96
20100069479
2010-03-18

NEURODEGENERATIVE DISEASE TREATMENT USING JAK/STAT INHIBITION

 #97
20100047765
2010-02-25

Method for determining human immunodeficiency virus (HIV) coreceptor utilization by examining gp41 molecular determinants

 #98
20100028415
2010-02-04

Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus

 #99
20090274725
2009-11-05

Method for inducing cross-reactive immune responses to the human immunodeficiency virus (HIV) in a host by administering feline immunodeficiency virus (FIV) capsid (CA) or reverse transcriptase (RT) immunogens

 #100
20090099073
2009-04-16

Albumin Fusion Proteins

 #101
20090093402
2009-04-09

Albumin Fusion Proteins

 #102
20090092631
2009-04-09

GLYCOSYLATED SPECIFICITY EXCHANGERS THAT INDUCE AN ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) RESPONSE

 #103
20090023164
2009-01-22

Methods for the detection of HIV-1 antibodies employing polypeptides obtained from gag P6 protein

 #104
20080213886
2008-09-04

Albumin fusion proteins

 #105
20080167240
2008-07-10

Albumin Fusion Proteins

 #106
20080167239
2008-07-10

Albumin fusion proteins comprising insulin polypeptides

 #107
20080161243
2008-07-03

Albumin Fusion Proteins

 #108
20080153751
2008-06-26

G-CSF-albumin fusion proteins

 #109
20080146503
2008-06-19

Albumin fusion proteins

 #110
20080031890
2008-02-07

Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies

 #111
20070259815
2007-11-08

Albumin fusion proteins

 #112
20070244047
2007-10-18

Albumin fusion proteins

 #113
20070224679
2007-09-27

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

 #114
20060276396
2006-12-07

Albumin fusion proteins

 #115
20060194735
2006-08-31

Albumin fusion proteins

 #116
20060153865
2006-07-13

Antigenic peptides

 #117
20050208143
2005-09-22

Microparticles with adsorbent surfaces, methods of making same, and uses thereof

 #118
20050191319
2005-09-01

Microparticles with adsorbent surfaces, methods of making same, and uses thereof

 #119
20050186664
2005-08-25

Albumin fusion proteins comprising GLP-1 polypeptides